Applied Dna Sciences INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
BNB Plus Corp. has filed a registration statement for the resale of up to 10,864,122 shares of common stock by selling stockholders, primarily related to convertible preferred stock and warrants.
BNB Plus Corp. files an S-1/A to register 18.7 million shares for resale by selling stockholders, detailing its new BNB-focused digital asset treasury strategy and ongoing LineaRx biopharmaceutical business.
Applied DNA Sciences is shifting its primary focus to a BNB-focused digital asset treasury strategy, backed by a private placement raising up to $57.6 million, despite ongoing financial losses and going concern doubts.
Applied DNA Sciences has filed an amendment to its Form S-1 registration statement, pertaining to the resale of up to 41,640,625 shares of common stock issuable upon the exercise of outstanding warrants.
Applied DNA Sciences is registering for resale up to 41.6 million shares of common stock issuable upon the exercise of outstanding warrants held by selling stockholders.
Applied DNA Sciences is seeking to raise capital through an offering of units, each consisting of common stock or pre-funded warrants, Series A and B warrants, and placement agent warrants.
Applied DNA Sciences aims to raise approximately $8.97 million through a unit offering to further develop its Therapeutic DNA Production and MDx Testing Services.
Applied DNA Sciences is seeking to raise up to $10 million through the sale of units, each containing common stock or pre-funded warrants, and Series A and B warrants.
Applied DNA Sciences aims to raise capital to further develop its Therapeutic DNA Production and MDx Testing Services through a public offering of common stock, warrants, and pre-funded warrants.
Applied DNA Sciences is offering shares of common stock and warrants to fund the development of its Therapeutic DNA Production and MDx Testing Services.
Applied DNA Sciences has filed an amendment to its S-1 registration statement to allow selling stockholders to resell up to 11,288,122 shares of common stock underlying common warrants.
Applied DNA Sciences has filed a registration statement for the resale of up to 11,288,122 shares of common stock underlying outstanding warrants.